Psoriasis Drug from J&J Beats Enbrel in Study

As Johnson & Johnson awaits a decision from the Food and Drug Administration on experimental drug ustekinumab, the medicine beat Amgen's Enbrel in a head-to-head test for treatment of psoriasis.